Furthermore, high expression of PLBD1 predicted shorter OS and DSS of patients with SKCM (Figure 2A-D), shorter DSS of patients with LUAD (Figure 2A-D), shorter DFI of patients with PRAD (Supplementary Figure 3A-B), shorter PFI of patients with KIRC (Supplementary Figure 3C-D). Here, PLBD1 is linked to prostate adenocarcinoma.